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The Brucella abortus virB operon, consisting of 11 genes, virB1 to virB11, and two putative genes, orf12
(virB12) and orf13, encodes a type IV secretion system (T4SS) that is required for intracellular replication and
persistent infection in the mouse model. This study was undertaken to determine whether orf12 (virB12)
encodes an essential part of the T4SS apparatus. The virB12 gene was found to encode a 17-kDa protein, which
was detected in vitro in B. abortus grown to stationary phase. Mice infected with B. abortus 2308 produced an
antibody response to the protein encoded by virB12, showing that this gene is expressed during infection.
Expression of virB12 was not required for survival in J774 macrophages. VirB12 was also dispensable for the
persistence of B. abortus, B. melitensis, and B. suis in mice up to 4 weeks after infection, since deletion mutants
lacking virB12 were recovered from splenic tissue at wild-type levels. These results show that VirB12 is not
essential for the persistence of the human-pathogenic Brucella spp. in the mouse and macrophage models of
infection.
The type IV secretion system (T4SS) of Brucella spp. has
been shown to be a major virulence factor, as Brucella abortus,
B. suis, and B. melitensis mutants deficient in the T4SS are
highly attenuated both in tissue culture models of intracellular
survival and in the mouse model of persistent infection (3–6, 8,
9, 11, 12, 15, 22, 24, 28). The T4SS is encoded by the virB locus
located on chromosome II, which in B. suis was shown to
include virB1 to virB11 and orf12, with a second putative orf13
predicted in B. abortus (15, 16, 22). It was subsequently shown
that in B. suis, orf12 is transcribed together with virB11 on a
common transcript and that insertional mutagenesis of virB1
abrogated the transcription of orf12 (3), suggesting that virB1
to virB12 form a transcriptional unit. Based on this evidence,
orf12 was designated virB12 (3). The genes virB1 to virB11 are
conserved among T4SSs from other bacterial pathogens, in-
cluding Agrobacterium tumefaciens; however, homologues of
virB12 have not been found in association with T4SSs from
pathogenic bacteria other than Brucella spp. The closest ho-
mologues of VirB12 have been identified on the mercury re-
sistance plasmid pSB102 identified in the rhizosphere of alfalfa
(20) and on a cryptic conjugative plasmid, pIPO2T, isolated
from unidentified bacteria in the wheat rhizosphere (26).
Other proteins with sequence similarities to VirB12 include
the major outer membrane protein of Pseudomonas spp. (27,
30). Further analysis of the VirB12 protein sequence identified
an OmpA homology domain and a lipoprotein signal sequence.
Together, these characteristics suggest that VirB12 is a sur-
face-localized protein of Brucella spp. that may play a role in
interactions with host cells. We therefore sought to character-
ize VirB12 from B. abortus and to determine whether this
protein is required for persistent infection.
MATERIALS AND METHODS
Bacterial strains, media, and culture conditions. Bacterial strains used were
Brucella abortus 2308, Brucella melitensis 16 M, and Brucella suis 1330, and their
characteristics are listed in Table 1. Strains were routinely cultured on tryptic soy
agar (TSA; Difco/Becton-Dickinson, Sparks, MD) or in tryptic soy broth (TSB)
at 37°C on a rotary shaker. Bacterial inocula for infection of mice were cultured
on TSA plus 5% defibrinated sheep blood. Antibiotics, when required, were
added at the following concentrations: carbenicillin, 100 mg/liter; kanamycin
(Km), 100 mg/liter; and chloramphenicol, 5 to 30 mg/liter. All work with live
Brucella strains was performed at Biosafety Level 3.
Strain construction and recombinant DNA techniques. For construction of
virB12 deletion mutants in B. abortus (AK/ORF12), B. melitensis (MK/ORF12),
and B. suis (SK/ORF12), a pCR2.1 (Invitrogen)-based plasmid was generated
using a three-step cloning strategy. This method takes advantage of the organi-
zation of the pCR2.1 TOPO vector. Plasmid pCR2.1 TOPO contains two PstI
sites, and cleavage with PstI releases a fragment containing the 3 end of the lacZ
alpha fragment, the f1 origin, and the 5 end of the kanamycin resistance gene
(vector data are available from Invitrogen). Deletion of this 1.19-kb PstI frag-
ment disrupts the kanamycin resistance gene but does not affect plasmid repli-
cation, and therefore pCR2.1 TOPO was used to generate a construct for the
allelic exchange of virB12 with a deleted copy marked with a kanamycin resis-
tance gene. In the first cloning step, a fragment in the 5 region of virB12
(designated UP) was amplified from B. abortus genomic DNA using primers
ORF12K1-F and ORF12K1-R (Fig. 1). A fragment in the 3 region of virB12
(designated DN) was amplified using primers ORF12K2-F (with SmaI) and
ORF12K2-R. The resulting fragments were TOPO cloned into pCR2.1 to yield
the two plasmids pUP/ORF12 and pDN/ORF12.
The orientations of the cloned inserts in pUP/ORF12 and pDN/ORF12 were
determined by PCR and restriction analysis. Clones were identified that carry the
SmaI site of the 5 (UP)-virB12 fragment located at the end of the insert opposite
PstI in pUP/ORF12. For pDN/ORF12, clones were identified that carry the SmaI
site of the 3-virB12 fragment located at the same end of the cloned insert as PstI.
A 1,008-bp SmaI/PstI UP fragment of pUP/ORF12 was introduced into SmaI/
PstI-cleaved pDN/ORF12 (the kanamycin resistance gene of pCR2.1 was trun-
cated by this digestion) to link the UP and DN fragments of virB12 together. The
resulting plasmid, named pUD/ORF12, was selected for ampicillin resistance. In
the third cloning step, a 1.3-kb SmaI fragment of pUC4-KIXX (Pharmacia)
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containing the Tn5 kanamycin resistance gene was cloned into the SmaI site of
pUD/ORF12 to generate pUKD/ORF12.
Plasmid pUKD/ORF12 was introduced into B. abortus 2308, B. melitensis 16
M, and B. suis 1330 by electroporation, and recombinants resistant to kanamycin
and sensitive to carbenicillin (the resistance encoded on the backbone of pUKD/
ORF12) were screened. The resulting strains were designated AK/ORF12 (B.
abortus virB12::Km), MK/ORF12 (B. melitensis virB12::Km), and SK/ORF12 (B.
suis virB12::Km). The plasmids constructed in this work are listed in Table 1, and
the primers used in the construction of the plasmids are listed in Table 2. Plasmid
DNA was isolated using ion exchange columns from QIAGEN, and the orien-
tation of the cloned fragments in pUKD/ORF12 was confirmed by DNA se-
quencing. Standard methods were used for Southern blotting, PCR, restriction
endonuclease analyses, and ligation and transformation of plasmid DNA into
Escherichia coli (1). PCR products were cloned into pCR2.1-TOPO using a
TOPO-TA cloning kit (Invitrogen).
Cell lines. The mouse macrophage-like cell line J774A.1 (18), obtained from
ATCC, was cultured in Dulbecco’s modified Eagle’s medium (Gibco, Rockville,
MD) supplemented with 10% heat-inactivated fetal bovine serum, 1% nones-
sential amino acids, and 1 mM glutamine (DMEMsup). For macrophage killing
assays, 24-well microtiter plates were seeded with macrophages at concentrations
of 1  105 to 2  105 cells/well in 0.5-ml portions of DMEMsup and incubated
overnight at 37°C in 5% CO2. The inocula were prepared by growing with
shaking in TSB for 24 h and then subsequently diluting them in DMEMsup to
concentrations of 4  107 CFU/ml. Approximately 2  107 bacteria in 0.5 ml of
DMEMsup, containing a 1:1 mixture of the wild type and the isogenic mutant,
were added to each well of macrophages. Microtiter plates were centrifuged at
250  g for 5 min at room temperature in order to synchronize infection. Cells
were incubated for 20 min at 37°C in 5% CO2, free bacteria were removed by
three washes with phosphate-buffered saline (PBS), and the zero time point was
taken as described below. DMEMsup plus 50 g gentamicin per ml was added to
the wells, and the cells were incubated at 37°C in 5% CO2. After 1 h, the
DMEMsup plus 50 g/ml gentamicin was replaced with medium containing 25
g/ml gentamicin. Wells were sampled at 0 and 48 h after infection by aspirating
the medium, lysing the macrophages with 0.5 ml of 0.5% Tween 20, and rinsing
each well with 0.5 ml of PBS. Viable bacteria were quantified by dilution in sterile
PBS and plating on TSA and TSA plus Km.
Infection of mice. Female BALB/c ByJ mice were obtained from the Jackson
Laboratory (Bar Harbor, ME) and used at ages of 6 to 10 weeks. For mixed-
infection experiments, groups of four or five mice were inoculated intraperito-
neally (i.p.) with 0.5-ml portions of PBS containing 2  105 CFU of a 1:1 mixture
of B. abortus, B. melitensis, or B. suis wild type and the isogenic virB12 mutant.
Infected mice were held in microisolator cages in a Biosafety Level 3 facility. At
4 weeks postinfection, mice were euthanized by CO2 asphyxiation, and the
spleens were collected aseptically at necropsy. Spleens were homogenized in 3 ml
of PBS and serial dilutions of the homogenate plated on TSA and TSA contain-
ing kanamycin for enumeration of mutant and wild-type CFU.
For assaying VirB12-specific antibody responses, mice were infected i.p. with
1  105 CFU of B. abortus 2308 or of the B. abortus virB12 deletion mutant
AK/ORF12. Blood samples were collected from the saphenous vein at various
time points after infection. All animal experiments were approved by the Texas
A&M University Laboratory Animal Care and Use Committee and were con-
ducted in accordance with institutional guidelines.
Generation of polyclonal specific antisera. The gene encoding Bcsp31 (14) was
PCR amplified from B. abortus using primers F1499-F and F1499-R (Table 2)
and cloned into directional C-terminal His-tagged fusion protein expression
vector pET101 (Invitrogen). For generation of VirB12-specific antiserum, a
504-bp fragment of the virB12 gene was PCR amplified from B. abortus using
primers VirB11084F and VirB11563R (Table 2), cloned into pCR2.1 (Invitro-
gen), and subsequently cloned in pIVEX2.4bNdeI (Roche) with restriction en-
zymes NotI and PstI to generate an N-terminal fusion with the six-His tag. Both
Bcsp31-6xHis and 6xHis-VirB12 were overexpressed and purified according to
standard protocols (1) and used to raise polyclonal antisera in rabbits at the
Texas A&M Comparative Medicine Program facility. To eliminate background
reactivity to whole B. abortus, the VirB12 immune rabbit serum was affinity
purified using 6xHis-VirB12 bound to a HiTrap column (Amersham Pharmacia)
according to the manufacturer’s instructions.
Western blotting. Brucella cultures inoculated in tryptic soy broth to a starting
optical density at 600 nm of 0.01 were incubated at 37°C with shaking at 200 rpm.
After 18 h, the cultures’ optical densities at 600 nm were 1.2 to 1.5, and bacteria
were pelleted and resuspended in 1 Laemmli sample buffer and heated at
100°C for 5 min, and the total protein equivalent to 1  108 CFU per well was
loaded for separation by sodium dodecyl sulfate-polyacrylamide gel electro-
TABLE 1. Bacterial strains and plasmids
Strain or plasmid Relevant characteristic(s) Source or reference
Strains
Brucella abortus
2308 Wild type B. Deyoe
BA41 virB::mTn5Km2 (virB1 3 region) 11
BA114 virB10::mTn5Km2 11
ADH1 Nonpolar virB2 deletion mutant 8
ADH3 virB2::Km 8
ADH4.2 virB1-virB12::Km 8
AK/ORF12 virB12::Km This study
Brucella melitensis
16 M Wild type ATCC
MK/ORF12 virB12::Km This study
Brucella suis
1330 Wild type ATCC
SK/ORF12 virB12::Km This study
Escherichia coli
DH5 endA1hsdR17 (rK
 mK
) supE44 thi-1 recA1 gyrA relA1 (lacZYA-argF) U169
deoR(80dlacZM15)
29
BL21(DE3) F ompT gal [dcm] [lon] hsdSB (rB
 mB
) 	DE3 23
Plasmids
pCR2.1-TOPO TA cloning vector Invitrogen
pET101 Directional His-tagged fusion protein expression vector Invitrogen
pET/1499 Gene bcsp31 cloned in pET101 to express C-terminal His-tagged fusion protein This study
pUC4-KIXX Carries Tn5 kanamycin resistance cassette Pharmacia
pUKD/ORF12 PCR products of virB(988–1562) and virB(1796–2458) separated by a
kanamycin resistance cassette cloned into pCR2.1-TOPO
This study
pIVEX2.4bNdel Plasmid for generating His-tagged proteins Roche
pDS1 pIVEX2.4bNdel::virB12 This study
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phoresis (SDS-PAGE) (13). Proteins were transferred to polyvinylidene difluo-
ride (PVDF) membranes by electroblotting and were detected using polyclonal
rabbit serum and goat anti-rabbit immunoglobulin G (IgG) conjugated to horse-
radish peroxidase (HRP). HRP activity was detected with a chemiluminescent
substrate (NEN). To determine protein expression levels, immunoblots were
quantified by measuring the relative optical densities and areas of the corre-
sponding bands with a computerized image analysis system (AlphaImager 2200;
Alpha Innotech Corporation). Data were expressed as integrated density values
and calculated as ratios of VirB12 to Bcsp31 or VirB5 to Bcsp31.
Detection of VirB12-specific IgG in mouse serum. The presence of antibody
reactivities against the recombinant protein VirB12 of Brucella abortus in the
serum samples from 10 BALB/c mice infected with B. abortus 2308 and 5 mice
infected with B. abortus AK/ORF12 (virB12) was determined by indirect enzyme-
linked immunosorbent assay (ELISA). Ni-nitrilotriacetic acid HisSorb plates
from QIAGEN (Valencia, CA) were coated with 100 ng of 6xHis-VirB12 per
well in PBS with 0.2% BSA (PBS-B), and plates were incubated at 4°C overnight.
After washing with PBS and 0.5% Tween 20 (PBS-T), the pooled serum samples
were diluted 1:100 in PBS-B and incubated overnight at 4°C. After washing with
PBS-T, the reactivity was measured using HRP anti-mouse IgG (1:1,000; BD
Pharmingen) by incubating the plates at 37°C for 1 h. The reaction was devel-
oped with Sigma Fast o-phenylenediamine dihydrochloride tablet sets. The re-
sulting color was read at 410 nm with an ELISA microplate reader (Dynatech
MR5000). Data points are the averages of duplicate dilutions, with each mea-
surement being performed twice.
Statistical methods. For macrophage killing assays, all experiments were per-
formed independently in triplicate at least three times, and data were expressed
as the geometric mean of the logs of CFU/well 
 standard deviation. For
competitive infection of mice, the mutant and wild-type CFU data were ex-
pressed as the mean of log-transformed CFU/spleen 
 standard deviation for
each group of four or five mice. For both in vitro and in vivo infections, com-
petitive indexes were calculated as log(CFU mutant/CFU wild type) and adjusted
in each case to the ratio of mutant to wild type in the inoculum. The statistical
significance of differences between mutants and wild types was determined by
paired Student’s t test. A P value of 0.05 was considered significant.
RESULTS
Construction and characterization of virB12 mutants. To
determine whether virB12 contributes an essential function to
the T4SS apparatus, we constructed mutants of B. abortus, B.
melitensis, and B. suis, each carrying an internal 334-bp dele-
tion marked by the Tn5 kanamycin resistance gene (see Ma-
terials and Methods for details on the construction). Since a
predicted orf13 overlaps the first 99 bp of virB12 in B. abortus
(22), we designed a deletion construct that left the first 143 bp
of virB12 intact. Expression of this fragment would be expected
to result in a 48-amino-acid N-terminal fragment containing a
predicted lipoprotein signal sequence, which after cleavage
would be predicted to yield a 33-amino-acid N-terminal frag-
ment of a putative VirB12 protein (Fig. 1).
Plasmid pUKD/ORF12, carrying a copy of virB12 with an
internal deletion of 334 bp replaced by the Tn5 kanamycin
resistance gene, was constructed (see Materials and Methods)
FIG. 1. Construction of virB12 deletion mutants in Brucella. Top: Diagram showing overlap of a putative orf13 with the 5 end of virB12. Bent
arrows indicate the primers used for construction of virB12 deletion mutants. Middle: Map of pUKD/ORF12 showing KIXX flanked by upstream
and downstream fragments cloned into the 2.7-kb pCR2.1 backbone (dotted line). The dotted arrow indicates the unique PstI site. Bottom:
Replacement of an internal fragment of virB12 with KIXX does not disrupt the predicted orf13. The numbering of the virB12 deletion corresponds
to that of the B. abortus virB operon in GenBank accession number AF226278 (22).
TABLE 2. List of primers
Primer name Primer sequence
F1499-F.....................5-CACCATGAAATTCGGAAGCAAAATC-3
F1499-R ....................5-TTTCAGCACGCCCGC-3
ORF12K1-F..............5-ACTGGAAGACTATGCGCAG-3
ORF12K1-R.............5-ACCCGGGAAAACCTGCAAGCGCAG-3
ORF12K2-F..............5-ACCCGGGATATCGAAATTTTACGC-3
ORF12K2-R.............5-AGCATATCCTGCGACATGC-3
ORF12C-F................5-ACATATGCGCACATTGGTTATGGTC-3
ORF12C-R ...............5-AGTCGACCTTGCGTAAAATTTCGATATC-3
ORF12I-F .................5-AGAACCCACCGCGCAAGC-3
virB2C-F ...................5-ACATATGAAAACCGCTTCCCCCAG-3
virB2C-R...................5-ACTCGAGCCTAAGCAGGTAAGAGGC-3
virB11084F ...............5-GCGGCCGCTCCAGCCCGCCGAAGCCG-3
virB11563R...............5-CTGCAGGAAAATGCGTGTCTTTGCGATAGGC-3
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and introduced into B. abortus 2308, B. melitensis 16 M, and B.
suis 1330 by electroporation. Recombinants resistant to kana-
mycin and sensitive to carbenicillin (the resistance encoded on
pUKD/ORF12) were identified, and the resulting strains were
designated AK/ORF12 (B. abortus virB12), MK/ORF12 (B.
melitensis virB12), and SK/ORF12 (B. suis virB12) (Fig. 1).
These strains were screened by PCR for the replacement of the
334-bp virB12 fragment by the Tn5 kanamycin resistance gene
(1.4 kb) (Fig. 2A). This result was confirmed by a Southern blot
of chromosomal DNA with a probe containing the deleted
region of virB12 (Fig. 2B). All three wild-type Brucella strains
and all three virB12 mutant strains hybridized with a virB2
probe, but the three virB12 deletion strains failed to hybridize
with the virB12 probe, demonstrating that this part of the
virB12 gene was deleted in all three virB12 mutants. As a
further control, we generated and purified a 6xHis-VirB12
fusion protein (see Materials and Methods) and raised a poly-
clonal rabbit serum specific for VirB12. On Western blots, the
antiserum reacted with a protein of approximately 17 kDa in
lysates of B. abortus 2308, B. melitensis 16 M, and B. suis 1330
(Fig. 2C) grown to stationary phase in TSB. No proteins were
detected in lysates any of these three virB12 mutants with this
antiserum. Consistent with previous reports describing expres-
sion conditions for the virB genes, we found that virB12 was
expressed at lower levels by B. suis than by B. abortus or B.
melitensis under these growth conditions (3, 19). These results
provide the first evidence that virB12 encodes a protein.
B. abortus mutants with polar insertions in the virB operon
still express virB12. In order to determine whether B. abortus
virB12 is coregulated with other genes in the virB operon, we
assayed levels of VirB12 protein and compared them to levels
of VirB5, whose expression was reduced by polar insertions in
virB1 and virB2 (8). As a basis for comparison, we used the
protein Bcsp31 (14). Bcsp31 is an immunogenic periplasmic
protein that is not required for the growth of B. abortus in
cultured epithelial cells or macrophages (10, 17). Our previous
results (not shown) indicated that the abundance of Bcsp31 in
B. abortus was not affected by mutations in the virB operon.
Polar mutations in the virB1 to virB2 intergenic region (BA41)
or in virB2 (ADH1) reduced the detection of VirB5 to a
greater extent than they did that of VirB12. A transposon
insertion in virB10 reduced the abundance of VirB12 but not of
VirB5, suggesting that this insertion is polar on the virB12
expression. As expected, no VirB12 was detected in the virB12
mutant AK/ORF12, and neither VirB5 nor VirB12 was de-
tected in the virB1 to virB12 operon deletion mutant, ADH4.2.
These results suggest that polar mutations in the operon up-
stream of virB5 exert a greater effect on the expression of virB5
than they do on the expression of the downstream gene virB12.
B. abortus produces VirB12 protein during infection of mice.
If virB12 is expressed during in vivo infection, then we would
expect an infected host to develop an antibody response, since
VirB12 was highly immunogenic in rabbits. To determine
whether virB12 is expressed during infections of a model host
with Brucella spp., we assayed for VirB12-specific IgG in sera
from mice infected with B. abortus 2308 or virB12 mutant
AK/ORF12. The results of ELISAs depicted in Fig. 3 show that
the titer of IgG specific for 6xHis-VirB12 increases above the
titer of naı¨ve mice, starting at 21 days after infection. Titers of
VirB12-specific IgG increased until 56 days postinfection, after
FIG. 2. Characterization of virB12 mutants. (A) Confirmation of virB12 deletion by PCR. Chromosomal DNAs of B. abortus 2308, B. melitensis
16 M, and B. suis 1330 and their respective virB12 mutants were amplified with primer pair ORF12C-F and ORF12C-R (Fig. 1 and Table 2).
Wild-type strains yield an amplicon of 520 bp of virB12, while mutants yield one of 1.3 kb, since they contain the Km resistance determinant KIXX.
(B) Confirmation of virB12 deletion by Southern blotting. EcoRI-digested genomic DNAs of wild-type Brucella strains and virB12 mutants were
hybridized with either a virB2 probe (corresponding to the sequence from 1609 to 1926 of B. abortus virB) or an internal virB12 probe
(corresponding to the sequence from 11181 to 11554 of B. abortus virB). The virB2 probe was generated by PCR using the primer pair virB2C-F
and virB2C-R. The virB12 probe was generated using primers ORF12I-F and ORF12C-R. Primer sequences are shown in Table 2. (C) Detection
of VirB12 protein in stationary-phase cultures of B. abortus 2308, B. melitensis 16 M, and B. suis 1330. Proteins from 1  108 CFU of
stationary-phase culture were separated on a 12% SDS-PAGE gel, transferred to a PVDF membrane, and probed with anti-VirB12 antiserum.
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which they remained at high levels through the end of the
experiment at day 70. For mice infected with AK/ORF12, the
IgG titers did not differ from the preinoculation titers over the
course of the experiment, showing that VirB12-specific anti-
bodies detected in mice infected with wild-type B. abortus are
not elicited by other cross-reactive B. abortus proteins. These
results indicate that VirB12 is synthesized and presented to the
host immune system during infections of mice.
Brucella mutants lacking virB12 survive in murine macro-
phages like their wild-type parent strains. To determine
whether VirB12 is required for intracellular survival of B. abor-
tus, B. melitensis, or B. suis, we assayed the ability of virB12
mutant strains to survive in J774A.1 macrophages. For these
experiments, we performed a coinfection of each virB12 mu-
tant with its respective wild-type strain, as coinfection gives a
sensitive measure of differences between the wild type and the
mutant with regard to intracellular survival (Fig. 4). Inocula
containing 1:1 mixtures of wild type and virB12 mutant were
used to infect J774A.1 cultures. Coinfection of B. abortus 2308
and B. abortus BA41 (virB1-virB2::mTn5Km2) showed that at
48 h after infection, the CFU of BA41 recovered was 1/100 of
that of B. abortus 2308, demonstrating that under these con-
ditions the wild type is not able to rescue a mutant lacking a
functional T4SS apparatus (Fig. 4). In contrast, the virB12
mutants AK/ORF12, MK/ORF12, and SK/ORF12 were recov-
ered from J774A.1 cells in numbers indistinguishable from
those of the wild type. These results show that VirB12 is not
required for the survival of B. abortus, B. melitensis, or B. suis
in this macrophage line.
Brucellamutants lacking virB12 persist in murine spleens at
wild-type levels. To test the ability of virB12 mutants to persist
in an animal model of infection, we used the murine model to
compare colonization levels of each virB12 mutant and its
virulent parent strain. To this end, we performed coinfection
studies with each mutant and its respective wild-type strain.
For mice, coinfection gives a sensitive readout of attenuation
with small experimental groups of animals. In addition, this
experimental design allowed us to assess whether VirB12 is
required for infection in the context of the host response to
wild-type B. abortus. Groups of four to five mice were infected
i.p. with inocula of 2  105 CFU containing 1:1 mixtures of the
mutant and the wild-type parent strain. While the B. abortus
virB mutant BA41 was not detected in the spleen by 4 weeks,
the numbers of CFU of virB12 mutants AK/ORF12, MK/
ORF12, and SK/ORF12 recovered from murine spleens were
not significantly different from those of the parent strains,
showing that virB12 is not essential for persistence in this
infection model (Fig. 5).
FIG. 3. VirB12-specific total IgG in serum samples of mice taken
after infection of BALB/c mice with B. abortus 2308 (n  10; filled
bars) or its isogenic virB12 mutant, AK/ORF12 (n  5; open bars).
Samples taken at the indicated time points postinfection were diluted
and measured by ELISA using His-VirB12 bound to HisSorb plates
(QIAGEN). Bars indicate the averages 
 standard deviations of du-
plicate measurements. The dotted line represents the background re-
activity in mice before infection with B. abortus.
FIG. 4. Recovery of B. abortus, B. suis, and B. melitensis virB12
mutants after coinfection of J774 macrophages with their respective
wild-type strains (WTs). A mixed inoculum of the virB12 mutant and
the wild type was used to infect J774 cells, and intracellular bacteria
were recovered after 48 h as described in Materials and Methods. Data
shown are the means of three independent assays done in triplicate 

standard deviations and plotted logarithmically. Top: Log-transformed
CFU of the wild type and virB12 mutants recovered from J774 cells are
given. Bottom: Competitive index (C.I.), calculated as log(CFU mu-
tant/CFU wild type), is shown on the y axis. A significant difference ()
was seen only in the control experiment using B. abortus mutant BA41
(B. abortus virB1-virB2::mTn5) in comparison with the wild type (P 
0.04).
FIG. 5. Recovery of B. abortus, B. melitensis, and B. suis virB12
deletion mutants from mouse splenic tissue after mixed infection with
their respective wild-type strains (WTs). Bacteria were recovered 4
weeks after i.p. infections with 2  105 CFU of 1:1 mixtures of the wild
type and the virB12 mutant. Data shown are the averages of groups of
four or five mice
 standard deviations and are plotted logarithmically.
Top panel: Log-transformed CFU recovered from mouse spleens are
given for wild-type and virB12 mutant strains. The dashed line indi-
cates the limit of detection in the spleen. Bottom: Competitive index
(C.I.), calculated as log(CFU mutant/CFU wild type), is shown on the
y axis. A significant difference () was seen in the experiment using B.
abortus mutant BA41 (virB1-virB2::mTn5) in comparison with the wild
type (P  0.04).
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DISCUSSION
This study was undertaken to determine whether virB12
encodes an essential part of the T4SS of Brucella spp. The
results show that VirB12 is expressed during in vitro growth.
As with VirB5, VirB12 was expressed more highly in stationary
phase than in log phase (data not shown). It was shown pre-
viously that mutation of virB1 abolishes expression of both
virB7 and virB10 (21, 22), suggesting that polar mutations in
the virB operon should also be polar on virB12, if it is in fact
coregulated with the other virB genes. Furthermore, a virB1
mutation was shown to eliminate the transcription of virB12 in
B. suis (3). However, the finding that virB mutations that de-
creased virB5 expression exerted less of a polar effect on virB12
expression (Fig. 6) suggests that in B. abortus, regulatory ele-
ments other than the virB promoter may influence VirB12
protein levels. The differences between our data and the data
from B. suis may reflect different regulatory mechanisms, as the
regulatory mechanisms of the virB genes have been shown to
differ among the Brucella species (19, 21, 25), or they may
reflect differences in the sensitivities of the various methods
used to detect virB12 expression.
Evidence of virB12 expression was also detected in mice
infected with B. abortus (Fig. 3), as an IgG response specific for
VirB12 was elicited after infection with B. abortus 2308 but not
with virB12 mutant AK/ORF12. These results indicate that
VirB12 is an immunogenic protein in the context of the re-
sponse to B. abortus infection and provide indirect evidence for
the expression of the virB genes during infection of mice. The
cell surface localization of VirB12 may contribute to its immu-
nogenicity. Cell surface proteins of B. abortus have previously
been shown to elicit antibody responses in mice (17), and it was
recently shown for Salmonella enterica serotype Typhimurium
that T-cell responses are preferentially directed against surface
antigens (2). It will be interesting to determine whether other
components of the Brucella T4SS elicit antibody or T-cell re-
sponses during infection.
To determine whether the expression of virB12 is required for
persistent infection by Brucella spp., deletion mutants were con-
structed from B. abortus, B. suis, and B. melitensis. In designing
these mutants, we considered that an orf13 overlapping virB12
was predicted in the B. abortus virB operon sequence (22). Al-
though orf13 has been annotated only for B. abortus, the DNA
sequence of this region is identical in B. abortus, B. suis, and B.
melitensis (7, 15, 16, 22). Since it is not yet known whether orf13
encodes a functional protein in any of the Brucella species, the
overlapping sequence was left intact in the virB12 mutants.
Expression of virB12 was not essential for growth in J774
cells or during the first 4 weeks of infection in mice. These
results do not rule out a role for VirB12 in interaction with
mucosal surfaces, since in our experiments this stage of infec-
tion was bypassed by using the i.p. route of inoculation. Fur-
ther, since the mouse is not a model for interactions with the
reproductive tract in ruminants, it is possible that VirB12 may
play a role during infection in the natural hosts of Brucella spp.
The ability of virB12 mutants to survive within macrophages
reported here differs from the phenotype reported by Boschi-
roli et al. for a B. suis virB12 mutant (3) but is in agreement
with the result reported by O’Callaghan et al. (15). Possible
FIG. 6. Effect of mutations in virB genes on VirB12 protein levels in B. abortus 2308. Top: Western blots. Proteins from 1  108 CFU of
stationary-phase culture were separated on a 12% SDS-PAGE gel and transferred to a PVDF membrane, which was followed by Western blotting
with polyclonal anti-VirB5 (1:500), anti-VirB12 (1:50,000), or anti-Bcsp31 (1:5,000) serum. Bottom: To determine protein expression levels,
immunoblots were quantified by measuring the relative optical densities and areas of the corresponding bands with a computerized image analysis
system as described in Materials and Methods. Data were expressed as integrated density values and calculated as ratios of VirB5 to Bcsp31 or
VirB12 to Bcsp31. Relative protein expression levels were plotted and compared with that of the wild type (WT), which was set to 1. The strain
names corresponding to the genotypes shown are listed in Table 1. Data shown is from a single experiment that was representative of three
independent experiments.
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explanations for the differences in these results include differ-
ences in the mutant construction (our mutant is a deletion
mutant, whereas the virB12 mutant reported by Boschiroli et
al. is an insertion mutant). Since the previous studies of the B.
suis virB12 mutants were performed using the human-derived
THP-1 macrophage line, we tested whether the intracellular
survival defect of virB12 mutants could be specific for human
macrophages. However, as with the mouse macrophage line,
none of the virB12 mutants constructed in this study exhibited
survival defects in THP-1 cells (data not shown).
Homologues of virB12 are missing from other pathogenic
bacteria with T4SS, but two conjugative plasmids from the
rhizosphere of wheat, alfalfa, and tomato plants, pIPO2 and
pSB102 (20, 26), contain highly conserved VirB12 homologues
that are predicted to play a role in mating pair formation.
Hence, it is possible that in Brucella spp., VirB12 may play a
role in interactions between cells, such as would occur during
conjugation, or, alternatively, that the virB12 gene may be an
evolutionary remnant of the acquisition of the virB genes by an
ancestor of Brucella spp. Further experimentation will be re-
quired to determine whether VirB12 plays a role in DNA
transfer or in infection of other animal hosts.
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